A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

作者：Mariko Honma, Naoto Suzuki, Mikako Goto, Taku Obara, Yoshiyuki Saito, Ken Nakajima, Ritsuko Yamane, Kunihiko Takahashi, Takeo Nakayama, Masahiro Hayashi, Atsuko Murashima, Akira Toyama · 发表于：Congenital Anomalies · 年份：2024 · DOI：10.1111/cga.12588 · 被引用次数：4 · 研究领域：Pregnancy and Medication Impact、Assisted Reproductive Technology and Twin Pregnancy、Preterm Birth and Chorioamnionitis

We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.